Document:

Employment Agreement

 Exhibit 10.13 
 EXECUTIVE EMPLOYMENT AGREEMENT 
 THIS EXECUTIVE EMPLOYMENT AGREEMENT (this
“Agreement”) is made and entered into effective as of March 16, 2010 by and between ACADIA Pharmaceuticals Inc., a Delaware Corporation (the “Company”), and Glenn F. Baity (“EXECUTIVE”). The Company and EXECUTIVE
are hereinafter collectively referred to as the “Parties”, and individually referred to each as a “Party”. 

RECITALS 

A. WHEREAS, the Company desires assurance of the continued association and services of EXECUTIVE in order to retain EXECUTIVE’s
experience, skills, abilities, background and knowledge, and is willing to confirm the continued engagement of EXECUTIVE’s services on the terms and conditions set forth in this Agreement; and 

B. WHEREAS, EXECUTIVE desires to continue in the employment of the Company, and is willing to continue such employment on the terms and
conditions set forth in this Agreement. 
 AGREEMENT 

In consideration of the foregoing promises and the mutual covenants herein contained, and for the other good and valuable consideration,
the Parties, intending to be legally bound, agree as follows: 
 1. Employment. 

1.1 The Company hereby employs EXECUTIVE, and EXECUTIVE hereby accepts employment by the Company, upon the terms and conditions set forth
in this Agreement for the period beginning on the date hereof and shall be an at-will employee. 
 1.2 EXECUTIVE shall serve as
Vice President, General Counsel and Secretary of the Company, and shall have the normal duties, responsibilities and authority of such office, unless otherwise determined from time to time by the Company’s Board of Directors. EXECUTIVE shall do
and perform all services, acts, or responsibilities necessary or advisable to carry out the job duties of Vice President, General Counsel and Secretary of the Company as assigned by the Company, provided, however, that at all times during his
employment EXECUTIVE shall be subject to the direction and policies from time to time established by the Board of Directors of the Company. 

2. Loyal and Conscientious Performance. 
 2.1 During his employment with the Company, EXECUTIVE shall devote sufficient energy, abilities and productive time to the proper and efficient performance of this Agreement necessary to properly carry
out the duties of Vice President, General Counsel and Secretary of the Company. 

 3. Compensation. 
 3.1 Beginning with the Effective Date of this Agreement, Company shall pay EXECUTIVE a salary (the “Base Salary”) of $275,000 per year, payable twice monthly in accordance with the
Company’s normal payroll practices. The Base Salary may be subject to annual increases by the Company’s Board of Directors (the “Board”) based on any recommendations from the Compensation Committee (the “Compensation
Committee”) of the Board. 
 3.2 In connection with this Agreement, EXECUTIVE shall also receive from the Company an
additional stock option granting EXECUTIVE the right to purchase 150,000 shares of the Company’s common stock under the Company’s 2004 Equity Incentive Plan (the “2004 Plan”) at the fair market value, as determined in accordance
with the terms of the 2004 Plan, including the customary change in control provision used for the Company’s executive officers. The terms and conditions of this grant of stock option shall be set forth in a separate stock option agreement. The
Parties acknowledge and confirm that this stock option is in addition to the stock option rights EXECUTIVE currently holds. 

3.3 In addition to the Base Salary payable to EXECUTIVE hereunder, the EXECUTIVE shall be entitled to the following benefits: 

3.3.1 All benefits to which all other executive officers of the Company generally are entitled as determined by the Company’s Board
of Directors, on terms comparable thereto, including but not limited to, participation in any and all 401(k) plans, bonus and incentive payment programs, group life insurance policies and plans, medical, health, dental and disability insurance
policies and plans, and the like, which may be maintained by the Company for the benefit of its Executive officers. 
 3.3.2
EXECUTIVE’s initial target bonus shall be 30% of Base Salary. The actual annual bonus, if any, will be determined by the Board following a recommendation from the Compensation Committee based on the EXECUTIVE’s and the Company’s
performance for the prior year and shall range from 0-150% of the target bonus. The Board, based on recommendations from the Compensation Committee, shall have the right to change the EXECUTIVE’s target bonus. 

3.4 The Company shall reimburse EXECUTIVE for all reasonable out-of-pocket expenses incurred by him in the course of performing his
duties under this Agreement, which are consistent with the Company’s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company’s requirements with respect to reporting
and documentation of such expenses pursuant to Company policy. 
 3.5 All of EXECUTIVE’s compensation shall be subject to
customary federal and state withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company. 
 3.6 Change of Control. Should there be a change of control of the Company, or any other transactions in which the Company is not the surviving entity, then, as part of that transaction, the Company
will require the surviving entity to modify this Agreement in an 

  
 2 

 
equitable manner to provide EXECUTIVE with the same Base Salary and benefits. Any unvested options granted to the EXECUTIVE hereunder shall fully vest in accordance with the terms of the
applicable option agreement. 
 4. Termination. 
 4.1 Termination for Cause. The Company shall terminate this Agreement for Cause (as defined herein) by delivery of written notice to EXECUTIVE specifying the cause or causes relied upon for such
termination. If EXECUTIVE’s employment under this Agreement is terminated by the Company for Cause before the last day of any calendar month, EXECUTIVE shall be entitled to receive as compensation for such calendar month, only the Base Salary
set forth in Section 4.1 prorated to the date of termination on the basis of a 30-day calendar month. Grounds for the Company to terminate this Agreement for “Cause” shall include only the occurrence of any of the following events:

 4.1.1 EXECUTIVE’s willful misconduct or gross negligence in the performance of his duties hereunder; 

4.1.2 EXECUTIVE’s willful failure or refusal to perform in the usual manner at the usual time those duties which he regularly and
routinely performs in connection with the business of the Company or such other duties reasonably related to the capacity in which he is employed hereunder which may be assigned to him by the Board of Directors of the Company, if such failure or
refusal has not been substantially cured to the satisfaction of the Board of Directors within thirty (30) days after written notice of such failure or refusal has been given by the Company to EXECUTIVE; 

4.1.3 EXECUTIVE’s performance of any action when specifically and reasonably instructed not to do so by the Board of Directors of
the Company; 
 4.1.4 EXECUTIVE engaging or in any manner participating in any activity which is directly competitive with or
intentionally injurious to the Company; 
 4.1.5 EXECUTIVE’s commission of any fraud against the Company or use or
appropriation for his personal use or benefit of any funds or properties of the Company not authorized by the Board of Directors to be so used or appropriated; or 
 4.1.6 EXECUTIVE’s conviction of any crime involving moral turpitude. 
 For
this purpose of this definition, no act or failure to act by the EXECUTIVE shall be considered “willful” or “grossly negligent” if the EXECUTIVE acted (or failed to act) in good faith with the reasonable belief that his actions
or omission was in the Company’s best interest. 
 Any notice of termination given pursuant to Section 5.1 shall
effect termination as of the date specified in such notice, or in the event no such date is specified, on the last day of the month in which such notice is delivered. 
 4.2 Termination Without Cause. The Company may voluntarily terminate this Agreement without Cause by giving written notice to EXECUTIVE. Any such notice shall

  
 3 

 
specify the exact date of termination (the “Termination Date”). If EXECUTIVE’s employment under this Agreement is terminated by the Company without Cause (as defined herein),
EXECUTIVE shall be entitled to receive a) his Base Salary and health insurance coverage, both at a rate existing at the date of termination for an additional 9 months after the Termination Date. All Base Salary payments shall be paid over time in
accordance with the Company’s general payroll practices, as and when such Base Salary would have been paid had EXECUTIVE’s employment not terminated; and b) any business expenses which are properly owing to the EXECUTIVE through the date
of termination. The EXECUTIVE shall not be under any obligation to mitigate the Company’s obligation by securing other employment or otherwise. 
 4.2.1 EXECUTIVE may voluntarily terminate this Agreement upon written notice of such termination submitted to the Chief Executive Officer or the Chief Financial Officer, and in such event EXECUTIVE shall
be entitled to receive all amounts due to him through the date of termination. 
 4.3 This Employment Agreement is a personal
services contract whereby the Company is engaging the services of EXECUTIVE. By entering into this Agreement, the Company is relying on EXECUTIVE performing his services for the Company throughout the entire term of this Agreement. 

5. Death or Disability During the Term of Employment. 
 5.1 This Agreement shall terminate without notice upon the date of EXECUTIVE’s death or the date when EXECUTIVE becomes “completely disabled” as that term is defined in Section 5.4.

 5.2 In the event of EXECUTIVE’s death, all rights of EXECUTIVE to compensation hereunder shall automatically terminate
immediately upon his death, except that EXECUTIVE’s heirs, personal representatives or estate shall be entitled to any unpaid portion of his salary and accrued benefits earned up to the date of his death. 

5.3 In the event EXECUTIVE is disabled, EXECUTIVE shall be entitled to receive such disability benefits as would apply to other executive
officers in the Company, subject to the terms and conditions of any such Company disability program. 
 5.4 The term
“completely disabled” as used in this Agreement shall mean the inability of EXECUTIVE to perform his duties under this Agreement because he has become permanently disabled within the meaning of any policy and disability income insurance
covering Executives of the Company then in force. In the event the Company has no policy of disability income insurance covering Executives of the Company in force when EXECUTIVE becomes disabled, the term “completely disabled” shall mean
the inability of EXECUTIVE to perform his normal and customary duties under this Agreement for a total of four (4) consecutive months by reason of any incapacity, physical or mental, based upon medical advice or an opinion provided by a
licensed physician acceptable to the Board of Directors of the Company, determines to have incapacitated EXECUTIVE from satisfactorily performing all of his usual services for the Company during the foreseeable future. The action of the Board of
Directors of the Company shall be final and binding and the date such action is taken shall be the date of such complete 

  
 4 

 
disability for purposes of this Agreement, and upon such date this Agreement shall become null and void and of no further force and effect. 

6. Assignment and Binding Effect. 
 6.1 This Agreement shall be binding upon and inure to the benefit of EXECUTIVE and EXECUTIVE’s heirs, executors, administrators, estate, beneficiaries, and legal representatives. Neither this
Agreement nor any rights or obligations under this Agreement shall be assignable by either party without the prior express written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the Company and its
successors, assigns and legal representatives. 
 7. Notices. 
 7.1 All notices or demands of any kind required or permitted to be given by the Company or EXECUTIVE under this Agreement shall be given in writing and shall be personally delivered (and receipted for) or
sent by facsimile (with confirmation of receipt), or sent by recognized commercial overnight courier, or mailed by certified mail, return receipt requested, postage prepaid, addressed as follows: 

If to the Company: 
 Attention: Human Resources 
 ACADIA Pharmaceuticals Inc. 

3911 Sorrento Valley Blvd. 
 San Diego, CA 92121 
 Fax 858-558-2872 

If to EXECUTIVE: 

Glenn F Baity 
 2437 Aster St. 
 San Diego, CA 92109 

Any such written notice shall be deemed received when personally delivered or upon receipt in the event of facsimile or overnight
courier, or three (3) days after its deposit in the United States mail by certified mail as specified above. Either Party may change its address for notices by giving notice to the other Party in the manner specified in this section.

 8. Choice of Law. 
 8.1 This Agreement is made in San Diego, California. This Agreement shall be construed and interpreted in accordance with the internal laws of the State of California. Each of the parties hereto agree to
the exclusive jurisdiction of the state and federal courts located in the State of California for any and all actions between the parties. Any controversy or claim arising out of or relating to this Agreement or breach thereof, whether involving
remedies at law or in equity, shall be adjudicated in San Diego County, California. 

  
 5 

 9. Integration. 
 9.1 This Agreement contains the entire agreement of the parties relating to the subject matter of this Agreement, and supersedes all prior oral and written employment agreements or arrangements between
the Parties. This Agreement cannot be amended or modified except by a written agreement signed by EXECUTIVE and the Company. 
 10.
Waiver. 
 10.1 No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except
with the written consent of the Party against whom the waiver is claimed, and any waiver of any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term,
covenant, condition or breach. No failure to exercise, delay in exercising, or single or partial exercise of any right, power or remedy by either party hereto shall constitute a waiver thereof or shall preclude any other or further exercise of the
same or any other right, power or remedy. 
 11. Severability. 
 11.1 The unenforceability, invalidity, or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. 

12. Interpretation; Construction. 
 12.1 The headings set forth in this Agreement are for convenience only and shall not be used in interpreting this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and
revised, or had an opportunity to review and revise, this Agreement, and the normal rule of construction to the effect any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement.

 13. Attorneys’ Fees. 
 13.1 In any controversy or claim arising out of or relating to this Agreement or the breach thereof, which results in legal action, proceeding or arbitration, the prevailing party in such action, as
determined by the court or arbitrator, shall be entitled to recover reasonable attorneys’ fees and costs incurred in such action. 
 14.
Counterparts. 
 14.1 This Agreement may be executed in any number of counterparts, each of which when so executed and
delivered shall together constitute an original thereof. 
 15. Representations and Warranties. 

15.1 EXECUTIVE represents and warrants that he is not restricted or prohibited, contractually or otherwise, from entering into and
performing each of the terms and covenants contained in this Agreement, and that his execution and performance of this Agreement will not violate or breach any other agreement between EXECUTIVE and any other person or entity. 

  
 6 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above
written. 
  

									
		 	ACADIA Pharmaceuticals Inc.	 	EXECUTIVE:
				
	By:	 	 /s/ Thomas H. Aasen
	 		 	 /s/ Glenn F. Baity

	Name:  Thomas H. Aasen	 		 	GLENN F. BAITY
	Title:   Executive Vice President, Chief Financial Officer and Chief Business Officer	 		 	

  
 7Termination Agreement

 EXHIBIT 10.24 
 TERMINATION AGREEMENT 
 This termination agreement (the
“Termination Agreement”) is made and entered into as of October 27, 2010 (the “Effective Date”), by and between Biovail Laboratories International SRL, a society with restricted liability established under the
laws of Barbados with its principal place of business at Welches, Christ Church, Barbados, West Indies (“BLS”) and ACADIA Pharmaceuticals Inc., a company organized under the laws of the State of Delaware with its principal place of
business at 3911 Sorrento Valley Boulevard, San Diego, California, United States (“ACADIA”). BLS and ACADIA are sometimes referred to herein individually as the “Party” or collectively as the
“Parties”. 
 RECITALS 
 WHEREAS, on May 1, 2009 BLS and ACADIA entered into that certain collaboration and license agreement, as amended by an amendment agreement dated October 5, 2009 (collectively, the
“Agreement”); 
 WHEREAS, pursuant to the Agreement, BLS acquired certain exclusive rights and licenses to
make, have made, use, sell, offer for sale and import Pimavanserin and Product in the Field in the United States and Canada and a license to conduct development and manufacturing activities in the Field outside the Territory solely for developing
and commercializing Product in the Field in the United States and Canada (as defined herein); 
 WHEREAS, in connection with the
recent merger between Biovail Corporation (the parent of BLS), and Valeant Pharmaceuticals International, the Parties have mutually agreed to terminate the Agreement, subject to the terms and conditions as set forth in this Termination Agreement.

 NOW, THEREFORE, in consideration of the foregoing promises and the mutual covenants contained herein, the Parties, intending
to be legally bound, agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Capitalized terms and phrases used herein and not otherwise defined or modified herein below shall have the respective meanings ascribed thereto in the Agreement. 

 

	1.1.	“ACADIA Releasees” has the meaning set forth in Section 3.1 hereof. 

 

	1.2.	“ACADIA Releasors” has the meaning set forth in Section 3.1 hereof. 

 

	1.3.	“Agreement” has the meaning set forth in the Recitals on the first page hereof. 

 

	1.4.	“BLS Licensed Patents” has the meaning set forth in Section 5.1 hereof. 

 

	1.5.	“BLS Releasees” has the meaning set forth in Section 3.1 hereof. 

	1.6.	“BLS Releasors” has the meaning set forth in Section 3.2 hereof. 

 

	1.7.	“Effective Date” shall be the date set forth on the first page hereinabove. 

 

	1.8.	“Party” or “Parties” has the meaning set forth in the recitals on the first page hereof. 

 

	1.9.	“Termination Agreement” has the meaning set forth in the recitals on the first page hereof. 

 

	1.10.	“Termination Consideration” has the meaning set forth in Section 6.1 hereof. 

ARTICLE 2 

TERMINATION OF THE AGREEMENT 
  

	2.1	The Parties mutually agree to terminate the Agreement as of the Effective Date and, as a result of such termination, the Parties hereby acknowledge and agree that,
except as expressly provided for under this Termination Agreement, their respective rights and obligations under the Agreement are hereby terminated as of the Effective Date and that both Parties shall have no further liability to each other under
the Agreement or with respect to the Agreement, except as expressly set forth in this Termination Agreement. 

  

	2.3	Upon the Effective Date, all rights and obligations of the Parties under the Agreement shall terminate, except those described in the following Articles and Sections of
the Agreement: Sections 2.4, 9.1, 10.3, 15.14, and Article 1, Article 8 and Article 11 of the Agreement. 

ARTICLE 3 

RELEASES 
  

	3.1	In consideration for the terms set forth in this Termination Agreement, ACADIA, on behalf of itself and its Affiliates, and the directors, officers, shareholders and
employees of such entities and the successors and assigns of the foregoing (the “ACADIA Releasors”), hereby releases BLS and its Affiliates and the directors, officers and employees of such entities (the “BLS
Releasees”) from any and all claims, actions, causes of action, liabilities, damages, judgements and demands of any kind, whether known or unknown that the ACADIA Releasors had, has, may have or ever claim to have against BLS Releasees
among, under or directly or indirectly related to the Agreement, except to the extent of rights and obligations of the Parties under the Agreement that survive as provided in Section 2.3 of this Termination Agreement. 

 

	3.2	 In consideration for the terms set forth in this Termination Agreement, BLS, on behalf of itself and its Affiliates, and the directors, officers,
shareholders and employees of such entities and the successors and assigns of the foregoing (the “BLS Releasors”), hereby releases ACADIA and its Affiliates and the directors, officers and employees of such entities (the
“ACADIA Releasees”) from any and all claims, actions, causes of action, liabilities, damages, and demands of any kind, whether known or unknown that the BLS 

	 	 
Releasors had, has, may have or ever claim to have against ACADIA Releasees among, under or directly or indirectly related to the Agreement, except to the extent of rights and obligations of the
Parties under the Agreement that survive as provided in Section 2.3 of this Termination Agreement. 

  

	3.3	This Termination Agreement shall not be construed to be an admission of liability or wrongdoing by any Party. The Parties further agree that neither this Termination
Agreement, nor the terms hereof or negotiations relating thereto, shall be offered in evidence in any proceeding for any purpose whatsoever, except to enforce the terms hereof or in any proceeding in which the terms of this Termination Agreement are
applicable. 

  

	3.4	Termination of the Agreement shall not relieve BLS of the surviving obligations set forth in Section 2.3 or the accrued obligations of BLS set out in Exhibit 1
(the “Accrued Obligations”). 

 ARTICLE 4 

TRANSITION MATTERS 
  

	4.1	To the extent permitted under Applicable Laws, BLS shall assign or cause to be assigned to ACADIA (or to the extent not so assignable, BLS shall take all reasonable
actions to make available to ACADIA the benefits of) any Regulatory Filings (including INDs, NDAs and Marketing Approval) for the Product in the Territory, if any, including any such Regulatory Filings made or owned by its Affiliates, Distributors
or Sublicensees, if any, at no cost to ACADIA. 

  

	4.2	BLS shall use Commercially Reasonable Efforts to (i) transition to ACADIA upon ACADIA’s request any arrangement with any contractor from which BLS had
arranged to obtain a supply of Pimavanserin or Product, to the extent permitted under BLS’s agreement with such contractor, and (ii) in connection with clause (b) of Section 6.1 of this Termination Agreement, transfer to ACADIA
all Product owned and controlled by BLS as of the Effective Date. 

  

	4.3	BLS shall use Commercially Reasonable Efforts to cooperate with ACADIA and/or its designee to effect a smooth and orderly transition in the development of Product in
the Territory for sixty (60) days from the Effective Date. 

 ARTICLE 5 

LICENCE 
  

	5.1.	BLS hereby grants to ACADIA (and causes its Affiliates to grant) a non-exclusive, royalty-free, fully paid and irrevocable license (with the right to grant sublicense
to ACADIA’s Affiliates and Third Parties) under such Know-How generated by or on behalf of BLS or its Affiliates prior to the Effective Date pursuant to this Agreement to the extent that such Know-How is necessary and solely useful for the use,
sale, offer for 

	5.2.	sale and/or importation of Pimavanserin or such Product in the Field in the Territory, to use, offer for sale, sell, have sold, and import Pimavanserin and Product in
the Territory. 

  

	5.3.	BLS represents and warrants to ACADIA, as of the Effective Date, as follows: (a) there were no BLS Patents generated by or on behalf of BLS or its Affiliates prior
to the Effective Date; (b) to the best of BLS’ knowledge, there were no Joint Patents generated by or on behalf of BLS or its Affiliates together with one or more employees, contractors, or agents of ACADIA and/or any ACADIA Affiliate; and
(c) there are no trademarks owned by BLS or its Affiliates solely related to the Product. Notwithstanding the foregoing representations in this Section 5.2, if any of those representations are inaccurate and there are items described in
any of clause (a), (b) or (c), then BLS or its Affiliates, as applicable, shall grant to ACADIA the applicable license contemplated by Section 13.5(g)(i) of the Agreement. 

ARTICLE 6 

BLS PAYMENT 
  

	6.1.	As consideration for the termination of the Agreement as set forth in this Termination Agreement, BLS shall provide the following consideration: (a) BLS shall pay
ACADIA the amount of eight million seven hundred and fifty thousand US dollars (US$8,750,000) and (b) BLS shall transfer to ACADIA all Product owned and controlled by BLS as of the Effective Date (collectively, the “Termination
Consideration”). The cash consideration included in the Termination Consideration and the Accrued Obligations shall be payable by BLS to ACADIA within 5 days of the Effective Date. 

ARTICLE 7 

GENERAL CONDITIONS 
  

	7.1.	Injunctive Relief. Either Party may seek immediate injunctive or other interim equitable relief as necessary to enforce the terms of this Termination Agreement,
provided that such relief is sought exclusively from a court as provided in Section 7.2 hereof. 

  

	7.2.	Jurisdiction. This Agreement and all questions regarding its existence, validity, interpretation, breach or performance of this Agreement, shall be governed by,
and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles with the exception of sections 5-1401 and 5-1402 of New York General Obligations Law. Any dispute
shall be finally settled by litigation brought solely in a United States Federal Court of competent jurisdiction (or state court if no Federal Court has jurisdiction) located in the State of New York, United States, and the Parties hereby submit to
the exclusive jurisdiction of such courts. 

  

	7.3.	Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but such counterparts, when taken together, shall
constitute one agreement. 

  

	7.4.	Binding Effect. This Agreement shall inure to the benefit of, and shall be binding upon, the Parties hereto and their respective legal representatives,
successors and assigns. 

	7.5.	Further Assurances. Each of ACADIA and BLS hereby agree to execute such further documents or instruments as may be necessary or appropriate to carry out the
intention of this Termination Agreement. 

  

	7.6.	Voluntary Agreement. The Parties have read this Termination Agreement and on the advice of counsel they have freely and voluntarily entered into this Termination
Agreement. 

  

	7.7.	Notice: Any notice to be given under this Termination Agreement shall be in writing and sent and delivered (i) by overnight courier of international
reputation (such as UPS, DHL or FedEx) (with delivery effective on the next business day) or (ii) by facsimile with transmission receipt (with delivery effective upon the date of transmission) to the following: 

ACADIA PHARMACEUTICALS INC. 
 Address: 3911 Sorrento Valley Boulevard, San Diego, CA 92121 
 Fax No.:
+1-858-320-8637 
 Attention: General Counsel 
 With a copy to (which shall not constitute notice): 
 COOLEY LLP

 Address: 4401 Eastgate Mall, San Diego, CA 92121-1909 

Fax No: 858-550-6420 
 Attention: Kay Chandler 
 BIOVAIL LABORATORIES INTERNATIONAL SRL

 Address: Welches, Christ Church, Barbados, West Indies. 

Fax No: 246-420-1532 
 Attention: Chief Operating Officer 
 With a copy to (which shall not constitute
notice): 
 VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 

Address: 7150 Mississauga Road, Mississauga, ON L5N 8M5. 
 Fax No: 905-286-3370 
 Attention: Legal Department 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. 

 

											
		 	 ACADIA PHARMACEUTICALS INC.
	 		 	 BIOVAIL LABORATORIES
 INTERNATIONAL SRL

				
	 Per:
	 	 /s/ Uli Hacksell
	 	 Per:
	 	 /s/ Michel Chouinard

	 Name:  Uli Hacksell
	 	Name:  Michel Chouinard
	 Title:   Chief Executive Officer
	 	Title:  Chief Operating Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]